TRCT
BIOA

Tower Research Capital (TRC)’s BioAge Labs BIOA Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.5K Buy
3,204
+332
+12% +$6K ﹤0.01% 2370
2026
Q1 		$50.2K Buy
2,872
+1,748
+156% +$33.7K ﹤0.01% 2737
2025
Q4 		$14.9K Sell
1,124
-1,471
-57% -$13K ﹤0.01% 3326
2025
Q3 		$15.3K Sell
2,595
-710
-21% -$3.33K ﹤0.01% 3552
2025
Q2 		$13.7K Buy
3,305
+901
+37% +$3.63K ﹤0.01% 3857
2025
Q1 		$9.04K Sell
2,404
-1,274
-35% -$5.89K ﹤0.01% 3831
2024
Q4 		$21.3K Buy
3,678
+3,641
+9,841% +$62.8K ﹤0.01% 3138
2024
Q3 		$770 Buy
+37
New +$741 ﹤0.01% 5268

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Tower Research Capital (TRC)'s BIOA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its BioAge Labs (BIOA) stake by 12% in Q2 2026, buying an estimated $6K and bringing the position to 3,204 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

Tower Research Capital (TRC) first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Tower Research Capital (TRC) held 3,204 shares of BioAge Labs worth $78.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 332 BioAge Labs shares in Q2 2026, an estimated $6K.
  • BioAge Labs made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2370 holding.
  • Tower Research Capital (TRC) first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.